<DOC>
	<DOCNO>NCT02732171</DOCNO>
	<brief_summary>This single center , prospective cross-sectional study woman complete therapy primary breast cancer within 5 year diagnosis increase risk relapse . Patients undergo screen bone marrow aspirate test presence disseminate tumor cell ( DTCs ) Patients harbor DTCs offer opportunity enrollment clinical trial therapy target DTCs prevent recurrence ( separate protocol ) .</brief_summary>
	<brief_title>PENN-Surveillance Markers Utility Recurrence After ( Neo ) Adjuvant Therapy Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Histologicallyconfirmed primary invasive breast cancer within 5 year study entry Pathologicallyconfirmed invasive breast cancer axillary lymph node tumor triple negative subtype : negative estrogen receptor ( ER ) , progesterone receptor ( PR ) Her2overexpression ASCOCAP guideline tumor Breast Cancer Recurrence Score ≥ 25 per Genomic Health Oncotype DX breast cancer test , residual disease neoadjuvant chemotherapy . Completed primary therapy ( surgery , ( neo ) adjuvant chemotherapy adjuvant radiation ) index malignancy No evidence local distant recurrent disease physical examination , blood test ( CBC , LFTs , Alk Phos ) , symptomdirected imaging , per NCCN guideline . Normal coagulation study : PT PTT ≤ 1.5 x upper limit normal per institutional laboratory range patient warfarin , INR &lt; 3.0 . For patient therapeutic anticoagulant , medication must clinically hold periprocedure per standard clinical management . Willing undergo bone marrow aspiration blood specimen collection per protocol specification Age 18 able give inform consent Patient evidence meeting exclusion criterion companion clinical trial . Concurrent enrollment another investigational therapy Patients receive chronic , high dose systemic treatment corticosteroid define : chronic use cortisone &gt; 50mg ; hydrocortisone &gt; 40mg , prednisone &gt; 10mg , methylprednisone &gt; 8mg dexamethasone &gt; 1.5mg ; another immunosuppressive agent . Topical inhale corticosteroid allow . Patients severe and/or uncontrolled medical condition condition could affect participation study : Symptomatic congestive heart failure New York heart Association Class III IV Unstable angina pectoris , myocardial infarction within 6 month start study drug , serious uncontrolled cardiac arrhythmia clinically significant cardiac disease Severely impaired lung function previously document spirometry DLCO 50 % normal predict value and/or 02 saturation 88 % less rest room air Uncontrolled diabetes Active ( acute chronic ) uncontrolled severe infection Liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis A known history HIV seropositivity report patient Impairment gastrointestinal function gastrointestinal disease ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) Patients active , bleed diathesis Female patient pregnant breast feed . Women childbearing potential must negative urine serum pregnancy test . Patients receive prior treatment mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) . Patients know hypersensitivity Everolimus rapamycins ( sirolimus , temsirolimus ) excipients A detailed assessment Hepatitis B/C medical history risk factor must do screening patient . HBV DNA HCV RNA PCR test require screening patient positive medical history base risk factor and/or confirmation prior HBV/HCV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>